ArticleGenes & cancer2010
Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer.
Article in Genes & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Benzotriazole in Cancer: A Systematic Review on Preclinical Evidence and Structure-Activity Relationship.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The role of VEGF in vascular dementia: impact of aging and cellular senescence.Biogerontology · 2025Review
- Article
- The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer.The Journal of international medical research · 2024Article
- Analysis of endothelial gene polymorphisms in Spanish patients with vascular dementia and Alzheimer´s disease.Scientific reports · 2023Article
- Design, Synthesis, Docking Study, and Antiproliferative Evaluation of Novel Schiff Base-Benzimidazole Hybrids with VEGFR-2 Inhibitory Activity.Molecules (Basel, Switzerland) · 2023Article
- Potent VEGFR-2 inhibitors for resistant breast cancer: a comprehensive 3D-QSAR, ADMET, molecular docking and MMPBSA calculation on triazolopyrazine derivatives.Frontiers in molecular biosciences · 2023Article
- Tetrahydrocurcumin-Related Vascular Protection: An Overview of the Findings from Animal Disease Models.Molecules (Basel, Switzerland) · 2022Review
- Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review.Pharmacogenomics and personalized medicine · 2022Article
- Comprehensive analysis ofFrontiers in molecular biosciences · 2022Article
- Killer Timing: The Temporal Uterine Natural Killer Cell Differentiation Pathway and Implications for Female Reproductive Health.Frontiers in endocrinology · 2022Review
- ORMDL3 Promotes Angiogenesis in Chronic Asthma Through the ERK1/2/VEGF/MMP-9 Pathway.Frontiers in pediatrics · 2021Article
- Correlation amongTranslational cancer research · 2020Article
- Merkel cell carcinoma of the thigh: case report and review of the literature.OncoTargets and therapy · 2019Article
- Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.Thoracic cancer · 2018Article
- Apatinib as targeted therapy for sarcoma.Oncotarget · 2018Review
- Ubiquitination of basal VEGFR2 regulates signal transduction and endothelial function.Biology open · 2017Article
- VEGFR2 Trafficking, Signaling and Proteolysis is Regulated by the Ubiquitin Isopeptidase USP8.Traffic (Copenhagen, Denmark) · 2016Article
- Effects of tetrahydrocurcumin on hypoxia-inducible factor-1α and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice.BioMed research international · 2015Article
- TGF-β1 induces the formation of vascular-like structures in embryoid bodies derived from human embryonic stem cells.Experimental and therapeutic medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ligands and their tyrosine kinase (TK) receptors regulate a variety of biological systems in animals. Vascular endothelial growth factor (VEGF) and its receptor (Flt/VEGFR family) system play a crucial role not only in physiological but also in most parts of pathological angiogenesis including cancer. Flt-1/VEGFR-1 and KDR/VEGFR-2 bind VEGF-A but have different functions on angiogenesis at early embryogenesis: Flt-1 has a negative role by trapping ligands, whereas KDR (Flk1 in mice) exerts a strong positive signal, resulting in a balance in blood vessel formation. At adult stages, however, both VEGFRs contribute to pathological angiogenesis either directly or through stimulation of migration/activation of macrophage lineage cells and stimulate tumor growth, metastasis, and inflammation. VEGFRs activate downstream signaling of the phospholipase Cγ-protein kinase C-MAP kinase pathway but not Ras pathway for cell proliferation. The VEGF-C/D and Flt-4/VEGFR-3 system regulates lymphangiogenesis. Thus, VEGFs as well as these receptor TKs are attractive targets for suppressing pathological angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.